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AbstrAct:
STAT transcription factors transduce signals from the cell surface to the nucleus, 
where they regulate the expression of genes that control proliferation, survival, self-
renewal, and other critical cellular functions. Under normal physiological conditions, 
the activation of STATs is tightly regulated. In cancer, by contrast, STAT proteins, 
particularly STAT3 and STAT5, become activated constitutively, thereby driving the 
malignant phenotype of cancer cells. Since these proteins are largely dispensable 
in the function of normal adult cells, STATs represent a potentially important target 
for cancer therapy. Although transcription factors have traditionally been viewed 
as suboptimal targets for pharmacological inhibition, chemical biology approaches 
have been particularly fruitful in identifying compounds that can modulate this 
pathway through a variety of mechanisms. STAT inhibitors have notable anti-cancer 
effects in many tumor systems, show synergy with other therapeutic modalities, 
and have the potential to eradicate tumor stem cells. Furthermore, STAT inhibitors 
identified  through  the  screening  of  chemical  libraries  can  then  be  employed  in 
large scale analyses such as gene expression profiling, RNA interference screens, 
or large-scale tumor cell line profiling. Data derived from these studies can then 
provide key insights into mechanisms of STAT signal transduction, as well as 
inform the rational design of targeted therapeutic strategies for cancer patients.
IntroductIon
The goal of research in cancer therapy is to 
develop  treatments  that  specifically  target  the  cancer 
cell while leaving normal cells intact. As basic scientific 
studies elucidate signaling pathways that are activated 
inappropriately in tumors and drive their pathogenesis, 
new therapeutic targets are emerging. One such pathway 
is the signal transducer activator of transcription (STAT) 
pathway, which allows extracellular cues to modulate 
gene expression [1]. Through the action of a variety 
of tyrosine kinases, STATs in the cytoplasm become 
phosphorylated on a critical tyrosine residue, thereby 
leading to an activating dimerization. These STAT 
dimers then enter the nucleus where they can modulate 
transcription of genes involved in key cellular processes 
such as survival and proliferation. Under physiological 
conditions, STATs are activated rapidly and transiently, 
reaching peak phosphorylation within minutes, and 
becoming dephosphorylated within one or two hours. 
However, in a wide range of human cancers, STATs, 
particularly STAT3 and STAT5, become activated 
constitutively, thereby driving increased expression of 
genes that directly lead to malignant cellular behavior 
[2]. Although STATs are critical for the pathogenesis of 
these tumors, they are largely dispensable in normal adult 
cells, suggesting that they would be targets with a high 
therapeutic index. Though transcription factors have not 
traditionally been thought of as druggable targets, the 
wide variety of cancers that depend on STATs for survival Oncotarget 2011; 2:  518 - 524 519 www.impactjournals.com/oncotarget
suggests that STATs may be attractive targets for cancer 
therapy.
chemIcAl bIology ApproAches to 
developIng stAt InhIbItors
To elucidate novel pharmacological strategies 
to modulate STAT-dependent gene expression, we 
developed a non-biased screen to identify compounds that 
could target any part of the STAT transcriptional pathway 
[3]. For this chemical biology approach, we generated a 
series of cell lines in which a luciferase reporter gene is 
under the inducible control of a single transcription factor. 
We then used these cell lines to screen diverse chemical 
libraries  to  identify  compounds  that  could  specifically 
block the function of a STAT family member. One could 
then deconvolute the mechanism by which the identified 
compounds mediated their effect, and this could reveal 
unappreciated targets for pharmacological intervention. 
We then took two parallel approaches for compound 
screening. We interrogated large diverse libraries 
comprised of approximately 200,000 compounds. In 
addition, to accelerate the development of proof-of-
concept clinical trials, we also screened libraries of drugs 
that were already known to be safe in humans. Using this 
approach, we identified nifuroxazide, which is approved 
in several countries for the treatment of diarrhea, as an 
inhibitor of STAT3. Nifuroxazide decreases STAT3 
tyrosine phosphorylation, and appears to do so by 
inhibiting Jak family tyrosine kinases, including Jak2 
and Tyk2. Reflecting the importance of this pathway in 
multiple myeloma (MM), nifuroxazide selectively reduces 
the viability of MM cells that contain constitutive STAT3 
activation. Nifuroxazide has a particularly strong effect 
at reducing the viability of MM cells overexpressing 
CKS1B, which is associated with poor prognosis in MM 
patients and which is associated with enhanced STAT3 
activation [4]. Therefore, using a non-biased approach, 
we have identified nifuroxazide as a STAT3 inhibitor that 
may be useful as a treatment for patients with MM.
This  screen  also  identified  the  anti-parasitic  drug 
pyrimethamine, which is approved in the United States 
for the treatment of toxoplasmosis and malaria, as being 
an effective STAT3 inhibitor. Pyrimethamine displays 
significant activity in vitro against multiple myeloma cell 
lines characterized by activation of STAT3 (Figure 1). 
However, it has little effect on myeloma cell lines lacking 
STAT3 activation, or on peripheral blood mononuclear 
cells (PBMC) harvested from healthy donors, which also 
lack STAT3 activation. Pyrimethamine exerts at least some 
of its anti-microbial effects as an inhibitor of dihydrofolate 
reductase (DHFR). However, this is unlikely to be the sole 
mechanism for its effect on STAT3 signaling, as other 
DHFR inhibitors, such as methotrexate, did not show 
activity in this screen.
stAt5 InhIbItIon In cml: pImozIde
A  third  STAT  inhibitor  that  we  identified  using 
this approach is the psychotropic drug pimozide, which 
is approved in the United States for treating Tourette’s 
syndrome [5]. This drug inhibits STAT5 function, and 
thus we performed our initial characterization in a disease 
in which the pathogenesis is dependent on constitutive 
STAT5 activation, chronic myelogenous leukemia (CML). 
CML is characterized by the essentially uniform finding 
Figure 1: pyrimethamine reduces the viability of multiple myeloma cell lines containing activated stAt3. Cells were 
incubated with the indicated concentrations of pyrimethamine for 48 hours, after which the relative number of viable cells was measured 
using an ATP-dependent luminescence assay. Multiple myeloma cell lines containing activated STAT3 (U266 and INA6) or lacking 
activated STAT3 (H929 and RPMI 8226) were tested, as were peripheral blood mononuclear cells (PBMC) harvested from healthy donors.Oncotarget 2011; 2:  518 - 524 520 www.impactjournals.com/oncotarget
of a chromosomal translocation between chromosomes 
9 and 22 yielding a fusion kinase BCR/ABL [6, 7]. 
Although the introduction of kinase inhibitors such as 
imatinib mesylate has revolutionized the treatment of 
this disease, several clinical challenges persist [8]. Some 
patients cannot tolerate the side effects from kinase 
inhibitors [9], and in others mutations arise in BCR/ABL 
rendering it resistant to the effect of kinase inhibitors 
[10]. In addition, kinase inhibitors do not eradicate the 
leukemic stem cell, and thus patients need to take these 
drugs indefinitely [11]. We found that pimozide inhibits 
the tyrosine phosphorylation of STAT5 in CML cells, 
raising the possibility that it may be a BCR/ABL inhibitor. 
However, several lines of evidence have suggested that 
this is not the case. First, there is no consistent loss of 
BCR/ABL autophosphorylation at concentrations that 
lead to STAT5 inhibition. Second, though the BCR/ABL 
inhibitor imatinib leads to a reduction in total cellular 
tyrosine phosphorylation, pimozide does not affect the 
phosphorylation of other substrates. Third, in vitro kinase 
assays show no effect of pimozide on BCR/ABL activity. 
In addition, BCR/ABL leads to the activation of pathways 
other than STAT5 in CML cells. Consequently, BCR/
ABL kinase inhibitors such as imatinib and nilotinib 
lead to a reduction in ERK MAP kinase (MAPK) 
phosphorylation; pimozide, by contrast, not only fails to 
decrease MAPK phosphorylation, but in fact leads to an 
increase in MAPK activation. This may be a result of a 
loss of expression of STAT5-dependent negative signaling 
regulators. Therefore, pimozide likely inhibits STAT5 
phosphorylation in a BCR/ABL-independent manner. 
The precise mechanism by which pimozide inhibits 
STAT5 is unknown, but preliminary studies suggest that 
it may alter the activity of negative regulators of STAT5 
phosphorylation.
The activation of MAPK in response to pimozide not 
only raises mechanistic questions, but it also provides a 
therapeutic opportunity. Though the inhibition of STAT5 
by pimozide reduces cell survival, it is possible that the 
accompanying activation of MAPK by pimozide provides 
pro-survival signals to the cell. This raised the possibility 
that inhibition of kinases upstream of MAPK might be 
particularly  beneficial  when  combined  with  pimozide. 
Treatment of CML cells with the MEK inhibitor UO126 
reduces the phosphorylation of MAPK, and this is seen 
even in the presence of pimozide. The combination of 
pimozide and UO126 leads to an increase in cytotoxicity 
when compared to cells treated with either drug alone. 
Therefore, dissecting the effects of inhibition of signaling 
pathways can provide crucial insights into maximizing the 
therapeutic potential of this approach.
If it is true that pimozide is functioning as a STAT5 
inhibitor downstream from BCR/ABL, then it would be 
expected that pimozide would be equally efficacious in 
inhibiting the viability of CML cells even in the presence 
of mutations in BCR/ABL that render them resistant to 
kinase inhibitors. Consistent with this possibility, we 
found that pimozide showed equal potency towards 
CML cells harboring wildtype BCR/ABL and BCR/ABL 
containing a T315I mutation which renders it resistant to 
all currently approved kinase inhibitors [12]. This effect 
may have even broader applicability in treating CML and 
other myeloproliferative diseases. In addition to mutations 
in BCR/ABL, it has been suggested that mutations in 
alternative pathways, such as Jak2, may result in imatinib 
resistance through activation of STAT5 [13-15]. A recent 
report suggests that the upregulation of STAT5 expression 
may also be part of the development of imatinib resistance 
[16]. All of these mechanisms require continued STAT5 
function, and thus inhibitors of this protein may be able to 
overcome resistance in a variety of settings.
One additional effect of STAT5 inhibition emerged 
from these experiments. As noted, CML patients need to 
take  kinase  inhibitors  indefinitely,  presumably  because 
these drugs do not eradicate the leukemic stem cell. To 
address this question, we examined the effect of pimozide 
on hematopoietic colony formation in vitro employing 
CD34+ cells isolated from the bone marrow of patients 
with CML or healthy donors. While pimozide had 
minimal effects on the cells from the healthy donors, it 
completely abrogated the ability of the cells from the 
CML patients to form colonies. This observation raises the 
possibility that pimozide or other STAT5 inhibitors, alone 
or perhaps in combination with a kinase inhibitor, may 
be able to eradicate leukemic stem cells. This is perhaps 
not surprising, in that some STAT target genes, such as 
BCL6 and KLF4, may play a critical role in maintaining 
pluripotency [17-19]. This is further supported by the 
finding that STAT3 activation may be a key event in breast 
cancer cells with stem cell-like properties [20].
stAt3 And stAt5 In cAncer 
pAthogenesIs
Although STAT3 and STAT5 have similar DNA 
binding sites, they have distinct biological roles. For 
example, in mammary epithelium, STAT5 is activated 
during pregnancy and lactation, while STAT3 is activated 
primarily during involution [21]. However, in cancer 
pathogenesis there is evidence that STAT3 and STAT5 
have similar functions [22]. There are many genes known 
to be regulated by both STAT3 and STAT5, including pro-
survival and proliferation genes such as Bcl-x, Mcl-1, and 
cyclin D1. In leukemias, STAT5 activation upregulates 
genes critical for tumor survival, whereas in multiple 
myeloma, STAT3 activates the same, or similar genes, 
which are critical for the pathogenesis of this tumor 
type. In addition, tumors that depend on the constitutive 
activation of one STAT may develop resistance to therapy 
through activation of another STAT family member. This 
can occur through the activation of other tyrosine kinases, 
through the autocrine secretion of cytokines, or through Oncotarget 2011; 2:  518 - 524 521 www.impactjournals.com/oncotarget
soluble or other signals derived from other cells, such as 
those found in the bone marrow stroma [13-15, 23]. For 
example, BCR/ABL activates STAT5 in the CML cell line 
K562, but when these cells are co-cultured with stromal 
cells, STAT3 is activated [24]. This activation of STAT3 
is correlated with resistance to the BCR/ABL inhibitors 
imatinib and nilotinib. Treatment of K562 cells with 
imatinib leads to an inhibition of STAT5 activation and 
a reduction in STAT5 target gene expression. However, 
K562 cells co-cultured with stromal cells continue to 
express these STAT target genes. Furthermore, reducing 
STAT3 levels with siRNA reversed the imatinib resistance 
seen under the co-culture conditions. Therefore, it is 
likely that STAT3 and STAT5 can both be oncogenic by 
regulating the expression of critical target genes. This also 
suggests that STAT inhibitors may be useful as therapeutic 
agents in cells that contain activation of either STAT3 or 
STAT5, or both.
Since STAT3 and STAT5 share overlapping 
regulatory pathways, we hypothesized that pimozide 
might inhibit STAT3 as well as STAT5. Although there 
are  some  cell  type-specific  restrictions  to  its  effects, 
pimozide readily inhibits STAT3 tyrosine phosphorylation 
in a number of systems, including the multiple myeloma 
cell lines INA6 (Figure 2) and U266 (data not shown). 
When myeloma cells are incubated with pimozide, there 
is a dose dependent loss of viability (data not shown). 
Since pimozide and pyrimethamine inhibit STAT3 
through distinct mechanisms, we reasoned that they may 
show a beneficial effect when combined. Various dose 
combinations of these drugs show enhanced effects on 
cell viability when compared to either drug alone (Figure 
3). This raises the possibility that simultaneously blocking 
STAT activation at two distinct steps may be a particularly 
effective form of therapy, and potentially less likely to 
allow the generation of resistance. 
leverAgIng the FIndIngs From 
cell-bAsed screens
Having  identified  compounds  that  inhibit  STATs, 
it then becomes possible to use these as probes to gain 
insight into the mechanisms of STAT signaling, identify 
specific targets for therapeutic intervention, and isolate 
even more effective drugs for therapeutic development. 
Gene expression profiling: The Connectivity Map
Although screening large numbers of compounds in 
a cell-based assay can rapidly identify a number of active 
STAT inhibitors, it can be a challenge to identify the 
mechanism by which these compounds exert their effect. 
One strategy is to identify other drugs whose mechanisms 
are better understood, and which exert similar actions. 
One approach to accomplish this is to obtain gene 
expression signatures from cells treated with a drug, and 
then to interrogate the Connectivity Map, a large database 
containing gene expression data derived from cells treated 
with over 1000 drugs [25]. This may identify other STAT 
inhibitors, which themselves may be useful for cancer 
therapy, and it may also help to clarify the mechanism 
of action of these drugs. It is also possible to use gene 
expression signatures of activated STAT3 to identify 
drugs that induce an inverse of this pattern as another 
computational strategy to identify STAT3 inhibitors.
rnA interference screening
A second large-scale approach to understand STAT 
signaling more clearly and elucidate the mechanism of 
action of newly identified STAT inhibitors is to use siRNA-
based screens in conjunction with the luciferase reporter 
cell lines described above. This approach can identify gene 
products that modulate STAT signaling, and may reveal 
Figure 2: pimozide reduces stAt3 tyrosine 
phosphorylation in multiple myeloma cells.  INA6 
myeloma cells were incubated with the indicated concentrations 
of pimozide for three hours, after which whole cell lysates were 
analyzed by immunoblot for tyrosine phosphorylated STAT3 
and total STAT3.
Figure 3: myeloma cell viability is reduced when treated 
with the combination of pimozide and pyrimethamine. 
INA6 multiple myeloma cells were treated with pyrimethamine 
(pyr) or pimozide (pim) or both. After 48 hours, the relative 
number of viable cells was measured using an ATP-dependent 
luminescence assay. Oncotarget 2011; 2:  518 - 524 522 www.impactjournals.com/oncotarget
hitherto unknown ways in which STAT signaling can be 
affected by other cellular pathways. RNA interference-
based screens can also be combined with newly identified 
STAT inhibitors to identify gene products that either 
abrogate the effect of the drugs, or which potentiate their 
effect. This strategy can help identify the direct cellular 
targets of these compounds, which may allow more 
traditional drug development approaches to be applied to 
them. In addition, the identification of pathways that may 
synergize with these STAT inhibitors can immediately 
suggest potentially synergistic therapeutic strategies that 
can be developed.
Large scale cell line-based efficacy screens
Given that STAT3 is known to be activated in a wide 
spectrum of human tumors, another strategy to evaluate the 
potential of STAT inhibitors is to determine their activity 
on a large panel of highly annotated cancer cell lines [26, 
27]. This approach can rapidly generate information on the 
activity of individual compounds against cell lines derived 
from particular tumor types, allows for analyses based 
on the genotype of cell lines, and provides a comparison 
of the activity of distinct STAT inhibitors evaluated 
through such a screen. Using a high throughput system, 
we screened over 600 adherent cells lines for sensitivity 
to pyrimethamine and pimozide. Importantly, not all the 
cell lines were sensitive to these drugs, confirming that 
they are not generally cytotoxic. Pyrimethamine was 
particular effective against cell lines from non-small cell 
lung cancers and skin cancers (principally melanoma), 
while pimozide showed preferential effectiveness against 
tumors from skin, esophagus, and head and neck, among 
others (Figure 4 and data not shown). All of these tumors 
have been reported to have frequent activation of STAT3, 
and  these  findings  support  a  common  final  target  of 
these drugs [28-30]. However, the sensitivities were not 
superimposable,  suggesting  that  there  are  drug-specific 
effects as well.
Since these cell lines have been genetically 
characterized, they can provide other clues regarding the 
effects of these drugs. For example, activating mutations in 
BRAF have been found to occur commonly in melanoma 
[31], and pimozide is more effective in tumors containing 
this mutation. Just as pimozide shows enhanced efficacy 
in CML when combined with BCR/ABL inhibitors, 
pimozide may be particularly useful in melanoma when 
combined with BRAF inhibitors [32, 33]. In addition, 
pimozide appears to be more effective in tumors that 
contain wildtype p53, which raises both mechanistic 
questions regarding STAT3 inhibitors in general and 
these  drugs  in  particular.  These  findings  also  suggest 
potential therapeutic strategies that could be employed 
to optimize the effects of these agents clinically. Thus, 
the  identification  of  targeted  STAT  inhibitors  through 
chemical biology processes can be leveraged by these 
additional large-scale analyses.
Figure 4: High throughput cell line profiling reveals distinct tumor type sensitivity to pyrimethamine.  684 human cancer 
cell lines were screened for the growth inhibitory effects of pyrimethamine, tested at three different concentrations, using previously 
described methods [26].  The tumor type enrichment algorithm indicates cell lines derived from different tumor types that show preferential 
sensitivity to pyrimethamine.  27% of the cell lines tested (vertical red line) were sensitive to pyrimethamine (defined as greater than 
80% killing at 10 μ M).  As a threshold for activity, greater than eight distinct cell lines of a particular tumor type had to show sensitivity 
to pyrimethamine (horizontal blue line).  Tumor types in the top right hand quadrant are significantly more sensitive to the drug and are 
indicated by red filled circles.Oncotarget 2011; 2:  518 - 524 523 www.impactjournals.com/oncotarget
conclusIon
Since  the  identification  of  the  STAT  transcription 
factor family in the early 1990s, abundant evidence has 
linked the inappropriate activation of these proteins with 
cancer pathogenesis. Given that these proteins may be 
relatively dispensable in mature cells, they represent 
targets with the potential of having a high therapeutic 
index. Although transcription factors have traditionally 
been  viewed  as  difficult  targets  for  pharmacological 
inhibition, chemical biology approaches have been 
useful  in  identifying  compounds  that  can  specifically 
inhibit these proteins through a variety of mechanisms. 
Furthermore, large scale strategies based on gene 
expression analysis, RNA interference, and cytotoxicity 
assays can then provide additional information related to 
both basic questions in STAT signal transduction, as well 
as the development of rational therapeutic strategies for 
cancer patients.
Acknowledgments
This work was supported by the National Cancer 
Institute and the Initiative for Chemical Genetics 
(Bethesda, MD), and was assisted by the Chemical 
Biology Platform of the Broad Institute of Harvard and 
MIT (Boston, MA). Support was also provided by the 
Multiple Myeloma Research Foundation (Norwalk, CT), 
the Kittredge Foundation (Dana-Farber Cancer Institute), 
the Brent Leahey Fund (Dana-Farber Cancer Institute), 
the Friends of the Dana-Farber Cancer Institute, and the 
Claudia Adams Barr Program in Innovative Basic Cancer 
Research (Dana-Farber Cancer Institute).
reFerences
1.  Paukku K, Silvennoinen O: STATs as critical mediators of 
signal transduction and transcription: lessons learned from 
STAT5. Cytokine Growth Factor Rev. 2004; 15:435-455.
2.  Frank DA: STAT signaling in cancer: Insights into 
pathogenesis and treatment strategies. Cancer Treat Res. 
2003; 115:267-291.
3.  Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima 
T, Ikeda H, Chauhan D, Anderson KC, Frank DA: 
Nifuroxazide inhibits survival of multiple myeloma cells 
by directly inhibiting STAT3. Blood. 2008; 112:5095-
5102.
4.  Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, 
Xiao F, Liu Y, Yang Y et al: Over-expression of CKS1B 
activates both MEK/ERK and JAK/STAT3 signaling 
pathways and promotes myeloma cell drug-resistance. 
Oncotarget. 2010; 1:22-33.
5.  Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett 
R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio 
MR et al: The STAT5 inhibitor pimozide decreases survival 
of chronic myelogenous leukemia cells resistant to kinase 
inhibitors. Blood. 2011; 117:3421-3429.
6.  Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL: 
Constitutive activation of STAT5 by the BCR-ABL 
oncogene in chronic myelogenous leukemia. Oncogene. 
1996; 13:247-254.
7.  Ye D, Wolff N, Li L, Zhang S, Ilaria RL, Jr.: STAT5 
signaling  is  required  for  the  efficient  induction  and 
maintenance of CML in mice. Blood. 2006; 107:4917-
4925.
8.  Savage DG, Antman KH: Imatinib mesylate--a new oral 
targeted therapy. N Engl J Med. 2002; 346:683-693.
9.  Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, 
Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, 
Abruzzese E et al: Multicenter independent assessment of 
outcomes in chronic myeloid leukemia patients treated with 
imatinib. J Natl Cancer Inst. 2011; 103:553-561.
10.  Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette 
R, Rao PN, Sawyers CL: Clinical resistance to STI-571 
cancer therapy caused by BCR-ABL gene mutation or 
amplification. Science. 2001; 293:876-880.
11.  Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn 
MJ, Richmond L, Holyoake TL: Primitive, quiescent, 
Philadelphia-positive stem cells from patients with chronic 
myeloid leukemia are insensitive to STI571 in vitro. Blood. 
2002; 99:319-325.
12.  Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis 
SG, Lee FY, Druker BJ, Deininger MW: Comparison of 
imatinib mesylate, dasatinib (BMS-354825), and nilotinib 
(AMN107) in an N-ethyl-N-nitrosourea (ENU)-based 
mutagenesis screen: high efficacy of drug combinations. 
Blood. 2006; 108:2332-2338.
13.  Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay 
KG, Poon LF, Xie Z, Palaniyandi S, Yu H et al: Enhanced 
activation of STAT pathways and overexpression of 
survivin confer resistance to FLT3 inhibitors and could be 
therapeutic targets in AML. Blood. 2009; 113:4052-4062.
14.  Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N, 
Preudhomme C, Quesnel B: BCR-ABL mutants spread 
resistance to non-mutated cells through a paracrine 
mechanism. Leukemia. 2008; 22:791-799.
15. Ito T, Tanaka H, Kimura A: Establishment and 
characterization of a novel imatinib-sensitive chronic 
myeloid leukemia cell line MYL, and an imatinib-resistant 
subline MYL-R showing overexpression of Lyn. Eur J 
Haematol. 2007; 78:417-431.
16.  Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-
Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer 
M, Hoermann G et al: High STAT5 levels mediate imatinib 
resistance and indicate disease progression in chronic 
myeloid leukemia. Blood. 2011; 117:3409-3420.
17.  Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson 
A,  Frank  DA:  Identification  of  a  genetic  signature  of 
activated signal transducer and activator of transcription 3 Oncotarget 2011; 2:  518 - 524 524 www.impactjournals.com/oncotarget
in human tumors. Cancer Res. 2005; 65:5054-5062.
18.  Li Y, McClintick J, Zhong L, Edenberg HJ, Yoder MC, 
Chan RJ: Murine embryonic stem cell differentiation 
is promoted by SOCS-3 and inhibited by the zinc finger 
transcription factor Klf4. Blood. 2004; 105:635-637.
19. Fukuda T, Yoshida T, Okada S, Hatano M, Miki T, 
Ishibashi K, Okabe S, Koseki H, Hirosawa S, Taniguchi 
M et al: Disruption of the Bcl6 gene results in an impaired 
germinal center formation. J Exp Med. 1997; 186:439-448.
20.  Marotta LL et al: Signaling pathways required by CD44+/
CD24- stem-cell-like breast cancer cells in human tumors. 
JCI. 2011; In press.
21. Bromberg J: Signal transducers and activators of 
transcription as regulators of growth, apoptosis and breast 
development. Breast Cancer Res. 2000; 2:86-90.
22. Benekli M, Baumann H, Wetzler M: Targeting signal 
transducer and activator of transcription signaling pathway 
in leukemias. J Clin Oncol. 2009; 27:4422-4432.
23.  Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl 
C, Ellwart JW, Hiddemann W, Spiekermann K: FLT3-
ITD-TKD dual mutants associated with AML confer 
resistance to FLT3 PTK inhibitors and cytotoxic agents by 
overexpression of Bcl-x(L). Blood. 2005; 105:3679-3685.
24. Bewry NN, Nair RR, Emmons MF, Boulware D, 
Pinilla-Ibarz J, Hazlehurst LA: Stat3 contributes to 
resistance toward BCR-ABL inhibitors in a bone marrow 
microenvironment model of drug resistance. Mol Cancer 
Ther. 2008; 7:3169-3175.
25.  Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel 
MJ, Lerner J, Brunet JP, Subramanian A, Ross KN et al: 
The Connectivity Map: using gene-expression signatures 
to connect small molecules, genes, and disease. Science. 
2006; 313:1929-1935.
26.  McDermott  U,  Sharma  SV,  Dowell  L,  Greninger  P, 
Montagut C, Lamb J, Archibald H, Raudales R, Tam A, 
Lee D et al: Identification of genotype-correlated sensitivity 
to selective kinase inhibitors by using high-throughput 
tumor cell line profiling. Proc Natl Acad Sci U S A. 2007; 
104:19936-19941.
27.  Sharma  SV,  Haber  DA,  Settleman  J:  Cell  line-based 
platforms to evaluate the therapeutic efficacy of candidate 
anticancer agents. Nat Rev Cancer. 2010; 10:241-253.
28. Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, 
Tweardy DJ, Abernethy JL, Edington HD, Donnelly SS, 
Becker D: Systemic interferon-alpha (IFN-alpha) treatment 
leads to Stat3 inactivation in melanoma precursor lesions. 
Mol Med. 1999; 5:11-20.
29. Leu CM, Wong FH, Chang C, Huang SF, Hu CP: 
Interleukin-6 acts as an antiapoptotic factor in human 
esophageal carcinoma cells through the activation of both 
STAT3 and mitogen-activated protein kinase pathways. 
Oncogene. 2003; 22:7809-7818.
30.  Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem 
MF, Endo S, Johnson DE, Huang L, He Y, Kim JD: 
Constitutive activation of Stat3 signaling abrogates 
apoptosis in squamous cell carcinogenesis in vivo. Proc 
Natl Acad Sci U S A. 2000; 97:4227-4232.
31. Pollock PM, Meltzer PS: A genome-based strategy 
uncovers frequent BRAF mutations in melanoma. Cancer 
Cell. 2002; 2:5-7.
32.  Vultur  A,  Villanueva  J,  Herlyn  M:  Targeting  BRAF  in 
advanced  melanoma:  a  first  step  toward  manageable 
disease. Clin Cancer Res. 2011; 17:1658-1663.
33. Corcoran RB, Settleman J, Engelman JA: Potential 
Therapeutic Strategies to Overcome Acquired Resistance 
to BRAF or MEK Inhibitors in BRAF Mutant Cancers. 
Oncotarget. 2011; 2:336-346.